Baxalta US Inc., a prominent biopharmaceutical company, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2015, Baxalta emerged from a spin-off of Baxter International, focusing on innovative therapies for rare diseases and complex conditions. The company is renowned for its expertise in haematology, immunology, and oncology, offering a range of unique products that address unmet medical needs. Baxalta's core offerings include advanced biologics and specialty pharmaceuticals, distinguished by their commitment to patient-centric solutions and cutting-edge research. With a strong market position, Baxalta has achieved notable milestones, including significant advancements in treatment options for bleeding disorders. The company continues to be a leader in the biopharmaceutical industry, dedicated to improving patient outcomes through innovation and excellence.
We don't have data for Baxalta Us Inc., but we can show you information about their parent organization instead.
View parent company